Equities
Health CarePharmaceuticals & Biotechnology
  • Price (EUR)5.57
  • Today's Change-0.095 / -1.68%
  • Shares traded163.32k
  • 1 Year change-4.87%
  • Beta0.3432
Data delayed at least 15 minutes, as of May 26 2020 16:38 BST.
More ▼

Profile data is unavailable for this security.

About the company

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

  • Revenue in EUR (TTM)68.97m
  • Net income in EUR-20.76m
  • Incorporated1999
  • Employees235.00
  • Location
    Innate Pharma SA117 avenue de Luminy, Bp 30191MARSEILLE 13009FranceFRA
  • Phone+33 430303030
  • Fax+33 430303000
  • Websitehttp://www.innate-pharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abivax SA-2.00k-22.75m274.03m25.00--15.42-----2.21-2.21-0.00021.46-0.00004-------45.21---61.90-------------24.320.5928-------93.39------
Valneva SE126.56m-7.83m338.68m508.00--2.57--2.68-0.087-0.0871.411.450.48651.947.96249,131.90-3.01-6.95-3.50-8.4260.6355.42-6.18-15.432.54-2.450.4272--11.6427.87-153.43--23.83--
AB Science SA1.57m-21.75m378.02m103.00------240.63-0.5573-0.55730.0399-0.6450.07810.94527.2615,252.43-108.11-76.90-2,891.89-171.1888.4884.76-1,384.28-1,469.310.7095-1,344.15-----7.64-5.6316.55---10.07--
Guerbet SA816.91m37.33m415.04m2.82k11.181.064.320.50812.952.9564.5031.010.78191.725.71289,683.003.574.225.246.1545.4050.314.575.401.29207.810.492624.603.4614.84-20.277.4013.976.96
Innate Pharma SA68.97m-20.76m446.56m235.00--2.05--6.47-0.2869-0.28691.032.760.1618--25.85293,506.40-4.87-3.91-7.77-5.6495.3593.44-30.10-23.54----0.1555---13.67137.80-780.85--94.61--
DBV Technologies SA13.14m-153.59m448.76m311.00--2.24--34.15-4.22-4.220.3553.650.06360.53941.2142,247.59-74.34-53.84-95.51-61.8892.6090.07-1,168.93-1,142.633.75-113.040.1176---9.6222.517.52--38.76--
Boiron SA557.12m40.63m576.37m3.50k14.161.147.321.032.322.3231.8128.870.72761.785.40159,087.105.308.786.6111.1177.1678.877.2810.922.47--0.025141.22-7.79-1.79-29.29-14.5210.24-6.89
Vetoquinol SA395.99m28.59m651.13m2.13k22.681.6815.551.642.422.4233.4732.650.81062.674.83--5.786.817.058.4547.9957.527.138.391.94387.070.014816.887.624.66-21.152.105.06-0.5182
Data as of May 26 2020. Currency figures normalised to Innate Pharma SA's reporting currency: Euro EUR

Institutional shareholders

4.10%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 07 May 2020643.48k0.82%
Wellington Management Co. LLPas of 31 Dec 2019359.94k0.46%
Schroder Investment Management Ltd.as of 31 Mar 2020341.52k0.43%
HSBC Global Asset Management (France) SAas of 31 Jan 2020320.87k0.41%
Sycomore Asset Management SAas of 30 Apr 2020306.96k0.39%
TIAA-CREF Investment Management LLCas of 31 Mar 2020286.31k0.36%
Goldman Sachs Asset Management LPas of 08 May 2020274.32k0.35%
OFI Asset Management SAas of 31 Jan 2019254.22k0.32%
Medical Strategy GmbHas of 31 Mar 2020248.37k0.32%
La Fran�aise Asset Management SASas of 31 Jan 2020200.00k0.25%
More ▼
Data from 31 Jan 2020 - 30 Apr 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.